Ligand Pharma (LGND) Tops Q3 EPS by 116c ; Offers Guidance

Ligand Pharma (NASDAQ: LGND) reported Q3 EPS of $3.09, $1.16 better than the analyst estimate of $1.93. Revenue for the quarter came in at $115.46 million versus the consensus estimate of $57.22 million.

GUIDANCE:

Ligand Pharma sees FY2025 EPS of $7.40-$7.65, versus the consensus of $6.87. Ligand Pharma sees FY2025 revenue of $225-235 million, versus the consensus of $212.8 million.

For earnings history and earnings-related data on Ligand Pharma (LGND) click here.

You May Also Be Interested In

• DocGo (DCGO) Misses Q2 EPS by 6c; Offers Guidance
• Wendy's U.S. president to resign, company to create COO role
• Ionic Digital backs Texas data center audit amid grid reliability push